Inside the Preclinical Toolkit for Measuring Brain Exposure

by November 17, 2026

Brain Diagram

The global neurological drug market is booming and is forecast to grow at a CAGR of 8.64% to exceed $285 billion by 2035. However, drugs targeting the central nervous system are notoriously difficult to develop, due to the complexity of delivering molecules beyond the blood-brain barrier (BBB).

Statistics back up the enormity of the challenge facing developers in this area. The global CNS drug success rate stands at 6%, while the failure rate of Phase II and III looms ominously over sponsors, at around 85%.

Two questions sit at the heart of preclinical work to develop drugs targeting the central nervous system (CNS): does the molecule reach the brain at an effective concentration, and can that be demonstrated with sufficient rigor to support IND-enabling decisions? To address these key points, developers and sponsors must ensure that researchers have the most effective tools in their preclinical toolkit, with approaches that can be applied across both small- and large-animal models.

CSF and Interstitial Fluid Sampling

One of the most effective ways of assessing drug exposure in the CNS is to sample fluid in and around the brain. The first method is cerebrospinal fluid (CSF) sampling, which can be performed via cisterna magna cannulation or puncture. This can achieve either single- or continuous-use CSF sampling.

However, CSF sampling should not be taken as definitive evidence of drug effectiveness in the CNS. Research can show that some drugs with high concentrations in tissues such as the hippocampus, cortex, and striatum don’t show the same levels in CSF. This raises the question of how effective CSF is in representing what is happening in the tissue.

The second method is to use microdialysis to sample brain interstitial fluid (ISF), which is the fluid in the tissue surrounding brain cells. This technique allows researchers to measure the free concentration of the drug in the ISF or blood, take continuous measurements from the same subject, calculate Kp,uu (used to assess unbound drug penetration into the brain) without in vitro assays, and measure biomarkers in the ISF.

Barrier Characterization and Bypassing the BBB

The BBB, a semipermeable barrier of endothelial cells that protects the brain from harmful or unwanted substances in the blood, is extremely complex and difficult to penetrate. This means knowing exactly how a drug candidate interacts with the BBB is essential.

One of the primary methods for barrier characterization is in situ brain perfusion, which is used to examine the combined effects of passive permeability and efflux transport. Researchers can use different perfusates to test different properties, while reducing the influence of first-pass liver metabolism and plasma protein binding. In short, this tells researchers how much of a drug is passing the BBB and what is stopping it.

Another way to deal with the BBB is bypassing it altogether. This means delivering the drug directly to the CNS and is useful for drugs that are poor at crossing the BBB. There are two major methods to bypass the BBB: Intracerebroventricular (ICV) administration and intrathecal administration. ICV delivers a drug directly into the cerebral ventricles, while intrathecal administration delivers the drug to the subarachnoid space, usually by injection into the lumbar region of the spinal canal.

Tissue Distribution and Precision

Researchers also need to establish exactly where a drug is found in the brain and how precisely it can be measured.

Brain Tissue Distribution Evaluation (QWBA/Tissue Sampling) can measure drug concentrations across different brain regions in small- and large-animal models and supports evaluation of efficacy and toxicity in the brain. This is crucial for understanding whether the part of the brain targeted by the drug candidate is reached.

Precision tissue dissection can provide a more accurate measure of drug concentration at the target site. This involves precision dissection of cerebrovascular vessels and brain parenchyma to accurately obtain drug concentrations at the target site. Evidence of the drug in a brain sample may simply be associated with the blood vessels running through the brain, rather than showing it has actually moved into the surrounding brain tissue, making precision even more important.

A Final Word on Preclinical Toolkits for Measuring Brain Exposure

These methods are integral to addressing the two essential questions in preclinical CNS exposure studies: whether the molecule reaches the brain at an effective concentration, and if the proof is rigorous enough to support IND-enabling decisions.

But there is another factor developers must consider to ensure the data garnered from these methods is as useful as possible: translational consistency. The goal here is to maintain consistency as programs progress from small to large animal models. By applying comparable experimental approaches across species and choosing models that remain biologically relevant to the drug, researchers can better compare results and achieve a more consistent PK dataset.

These methods and practices all help make CNS-targeting drug development a little less challenging, but risks and complexities will always remain. To ensure development does not falter due to costly delays and missteps, sponsors and developers should work with partners who possess the speed, quality, and expertise required to meet challenges head-on.

Discuss Program

Discuss Your Program with Us

Share your development goals and key challenges with our experts to define the right path forward.

Discuss Your Program